drugset
drugset / Trial / NCT04849286

Measurement of HTL0016878 in Cerebrospinal Fluid

NCT04849286 ↗

Phase 1 Completed 16 enrolled Nxera Pharma UK Limited
RandomizedParallel-groupOpen-labelTreatment

Summary

A Phase 1, open-label, randomised, single oral dose study to determine the concentration of HTL0016878 in CSF and plasma in healthy male subjects following dosing with HTL0016878 10 mg or 20 mg oral solution

Timeline

Start
2018-09-26
Primary completion
2018-12-07
Completion
2018-12-07

Drugs

EvaluationDrugModalityDoseRoute
Subject NBI-1117568 Unknown 10 mg Oral
Subject NBI-1117568 Unknown 20 mg Oral

Indications

No indication recorded.